obstructive airway disease


Also found in: Acronyms.

obstructive airway disease

[əbstruk′tiv]
any respiratory disease characterized by air trapping caused by either decreased airway diameter or increased airway secretions, or both. It includes chronic bronchitis and emphysema. See also chronic obstructive pulmonary disease, cystic fibrosis.

obstructive airway disease

A general term for any condition in which the movement of normal quantities of oxygen from the atmosphere to the blood is prejudiced. The term ‘chronic obstructive airway disease’ (COAD) is usually limited to chronic BRONCHITIS and EMPHYSEMA.
References in periodicals archive ?
Astudy on prevalenc of obstructive airway disease among post pulmonary tuberculosis patients.
b[sub]2 -agonists are by far the most effective bronchodilators for obstructive airway disease.
Moreover, anatomic factors such as chronic obstructive airway disease (which might have weakened the trachea) and tumor infiltration of peritracheal tissue might have also aggravated the tracheal injury.
ProAir[R] HFA was approved by the FDA in October 2004 for treatment or prevention of bronchospasm with reversible obstructive airway disease in adults and children 12 years of age and older.
The company's Levalbuterol Inhalation Solution is the generic version of Sunovion's Xopenex Inhalation Solution, which is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children six years of age and older with reversible obstructive airway disease.
This study will examine the possible acceleration of atherosclerotic plaque development, increased reactive or obstructive airway disease, reduced lung capacities, enhanced susceptibility to infectious agent exposures, and altered gene expression.
Asked whether they adhered to treatment for their reversible obstructive airway disease, 53 respondents did not answer the question and were excluded from analysis of the results.
Food and Drug Administration (FDA) has approved Xopenex[R] brand levalbuterol HCI inhalation solution for the treatment or prevention of bronchospasm in children 6 to 11 years old with reversible obstructive airway disease, such as asthma.
Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), chronic obstructive airway disease (COAD), chronic airflow limitation (CAL) and chronic obstructive respiratory disease (CORD), refers to chronic bronchitis and emphysema, a pair of commonly co-existing diseases of the lungs in which the airways become narrowed.
The solution is to be used for the treatment or prevention of bronchospasm in adults, adolescents, and children over 6 years of age with reversible obstructive airway disease.
The primary cause of obstructive airway disease in children is hypertrophy of the adenoid and faucial tonsils, and we recommend a surgical approach for management.
Sepracor's sales force has marketed XOPENEX brand levalbuterol HCl Inhalation Solution, which is a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in patients six years of age and older with reversible obstructive airway disease, since 1999.